pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,254 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1213Endpoints919BioPharma Dive354BioSpace340Fierce Biotech317onclive165raps111globenewswire health73
therapy area
allOncology8269Rare Disease1942Cardiology1880Immunology1589Hematology1354Vaccines1279Pulmonology
  • Food safety experts warn of talent loss at USDA amid broader health policy updates
    Food safety experts cautioned that the USDA is experiencing a significant loss of scientific talent, which could affect its ability to oversee food safety programs. The autism advisory committee,…
    STAT · 4mo agoNeutral↗ source
  • Alternative medicine often feels more personal than conventional care, says physician
    Dr. Hannah Kerman, a New York physician, writes that many patients turn to acupuncturists or massage therapists because they feel more attended to than during typical medical visits. She describes…
    STAT · 4mo agoNeutral↗ source
← prev
page 126 of 131
next →
fda medwatch68
fda recalls66
fda press38
1277
Psychiatry & CNS895
Ophthalmology521
Pain503
Endocrinology & Metabolism496
Infectious Disease459
Pfizer settles with generics to extend tafamidis patent until 2031, protecting revenue
Pfizer announced settlements with three generic manufacturers-Dexcel Pharma, Hikma Pharmaceuticals and Cipla-to delay the launch of generic versions of tafamidis, the active ingredient in its rare‑…
BioPharma Dive · 4mo agoDealPositive↗ source
  • Boehringer’s dual-acting obesity shot survodutide meets primary goal in Phase 3, showing strong weight loss and muscle-preserving effect
    Boehringer Ingelheim announced that its dual-acting injectable obesity therapy, survodutide, achieved its primary endpoint in a Phase 3 study. Participants receiving the drug lost significantly mo…
    BioPharma Dive · 4mo agoPositive readoutPositive↗ source
  • FDA urges Amgen to withdraw Tavneos after alleging data manipulation by former developer
    The FDA has sent a formal letter to Amgen recommending that the company pull its drug Tavneos from the market. The agency says new information shows the original approval filings from ChemoCentryx…
    BioPharma Dive · 4mo agoRegulatoryNegative↗ source
  • FDA says trial manipulation undermines approval of ChemoCentryx's Tavneos, now owned by Amgen
    The U.S. Food and Drug Administration has announced that it believes the pivotal trial supporting the approval of Tavneos was manipulated. The agency says ChemoCentryx, which was acquired by Amgen…
    Endpoints · 4mo agoRegulatoryNegative↗ source
  • Eli Lilly partners with AI startup Profluent to develop next-generation gene editors
    Eli Lilly announced a collaboration with AI-focused biotech Profluent to create advanced gene-editing tools that could insert whole genes into patients. The partnership is intended to move beyond…
    STAT · 4mo agoDealPositive↗ source
  • Incyte reports positive Phase 3 results for povorcitinib in nonsegmental vitiligo, plans FDA filing
    Incyte announced that its oral JAK1 inhibitor povorcitinib achieved positive outcomes in two Phase 3 trials targeting nonsegmental vitiligo. The studies met their primary endpoints, demonstrating…
    Endpoints · 4mo agoPositive readoutPositive↗ source
  • AbbVie eyes pan-RAS market with up to $1.45 B option to acquire Kestrel
    AbbVie announced it has signed an agreement that gives it the right to acquire Kestrel Therapeutics for up to $1.45 billion. The deal would give AbbVie access to Kestrel’s pipeline focused on pan-…
    Endpoints · 4mo agoDealPositive↗ source
  • Novartis CEO says Trump’s drug pricing plan creates a very difficult situation for makers and patients
    Novartis chief executive Vas Narasimhan warned that the United States drug‑pricing policy under President Trump presents a "very difficult situation" for both drugmakers and patients. He said the…
    STAT · 4mo agoRegulatoryNegative↗ source
  • BridgeBio's heart drug Attruby exceeds sales expectations, shifting investor outlook
    BridgeBio prepared to sell its heart drug Attruby on its own, prompting skepticism from investors and analysts who doubted the company could compete with larger rivals. The drug far outperformed f…
    BioPharma Dive · 4mo agoPositive↗ source
  • Novartis CEO warns of impact from Germany's €60 billion healthcare spending cuts
    Novartis chief executive Vas Narasimhan said the company is very disappointed by Germany's proposal to reduce healthcare spending by more than €60 billion. He expressed concern that the cuts could…
    Endpoints · 4mo agoRegulatoryNegative↗ source
  • AIDS advocacy group sues Trump administration over hidden Gilead HIV-prevention settlement
    The AIDS advocacy group PrEP4All filed a lawsuit against the Trump administration, alleging it failed to disclose a research and development agreement with Gilead Sciences. The agreement was part…
    STAT · 4mo agoRegulatoryNegative↗ source
  • FDA launches AI-driven pilot to review trial data in real time, aiming to speed clinical studies
    Washington officials said the Food and Drug Administration is starting a new program to speed clinical trials by reviewing data as it is generated. The first pilots will use real-time data from tr…
    STAT · 4mo agoRegulatoryPositive↗ source
  • FDA launches pilot to collect real-time clinical trial data
    The FDA announced a new pilot program that will gather clinical trial information as it is generated, allowing reviewers to see data in real time. The agency says this approach could speed up eval…
    Endpoints · 4mo agoRegulatoryNeutral↗ source
  • Pfizer secures two-year extension on Vyndamax patent, delaying competition
    Pfizer announced it has obtained an extension that pushes back the start of generic competition for its heart-failure drug Vyndamax (tafamidis) by about two years. Vyndamax ranks among Pfizer’s to…
    Endpoints · 4mo agoRegulatoryPositive↗ source
  • FDA commissioner touts real-time trial monitoring to cut drug development dead time
    The Food and Drug Administration announced a new approach that will let regulators view clinical trial endpoints as they happen, using cloud‑based data streams. The move targets the long delays th…
    STAT · 4mo agoRegulatoryPositive↗ source
  • Supreme Court to hear arguments on generic fish‑oil pill case, industry watches
    The U.S. Supreme Court is set to hear arguments this week on a case involving a prescription‑strength pill derived from fish oil. The dispute centers on whether the product qualifies as a generic…
    Endpoints · 4mo agoRegulatoryNeutral↗ source
  • Supreme Court to Hear Arguments on “Skinny Labeling” Case Impacting Generic Drug Access
    The U.S. Supreme Court scheduled oral arguments for Wednesday on a case concerning “skinny labeling,” a practice used by generic drug makers. Skinny labeling involves seeking approval to market a…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • BeOne Medicines licenses trispecific antibody targeting PD-1, CTLA-4 and VEGF from Chinese biotech
    BeOne Medicines, formerly known as BeiGene, announced a licensing agreement with a Chinese biotechnology firm to obtain rights to an experimental trispecific antibody. The antibody is engineered t…
    Endpoints · 4mo agoDealPositive↗ source
  • Coultreon secures $125M Series A to advance oral immune drug into Phase 2 trials
    Coultreon Biopharma announced a $125 million Series A financing round to fund development of an oral drug it licensed from Galapagos. The round was led by Sofinnova Investments and included nine i…
    BioPharma Dive · 4mo agoDealPositive↗ source
  • Coultreon Biopharma secures $125M to advance SIK inhibitor for autoimmune diseases
    Coultreon Biopharma announced a $125 million financing round on April 28, 2026, backed by major biotech investors from the United States and Europe. The capital will be used to develop a new appro…
    Endpoints · 4mo agoDealPositive↗ source
  • Boehringer's obesity injection shows 17% weight loss after 18 months, comparable to Wegovy but below Zepbound
    Boehringer Ingelheim, together with Zealand, released data from a late‑stage study of its experimental obesity injection. The trial followed patients for roughly a year and a half. Participants on…
    Endpoints · 4mo agoPositive readoutPositive↗ source
  • AI-driven admin tech continues to dominate health-tech funding landscape
    The article notes that administrative technology remains the leading segment within health‑tech investment. Startups that apply artificial intelligence to automate routine tasks such as patient fol…
    Endpoints · 4mo agoPositive↗ source
  • STAT+: Boehringer’s obesity drug shows 16.6% weight loss; more data needed
    Eli Lilly's deal with Profluent, Erasca's RAS-targeting cancer pill, and more biotech news today
    STAT · 4mo agoDealNeutral↗ source